Actinium 1st-in-Human Phase 1 Study of Non-PSMA Targeting Radiotherapy in Prostate Cancer

 

• Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC)
  
  
• Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a targeted radiotherapy
  
  
• ATNM-400 is a first-in-class, non-PSMA targeted radiotherapy being developed to address a broad mCRPC patient population, including PSMA-low and PSMA-negative disease and patients who do not respond to or progress following PSMA-directed therapies

https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-oral-presentation-at-eanm-2026-highlighting-first-in-human-phase-1-study-of-atnm-400-a-non-psma-targeting-radiotherapy-in-prostate-cancer-302909267.html